ASX Pharma Companies to Watch
The pharmaceutical industry continues to be a critical driver of healthcare innovation and investment opportunities. In 2025, several companies stand out for their robust pipelines, financial strength and pioneering technologies addressing some of the most pressing medical needs globally.
CSL Limited remains a dominant player in the biopharmaceutical sector propelled by its comprehensive portfolio spanning immunoglobulins, specialty products and vaccines. CSL delivered a solid 5% revenue growth to approximately US$8.5 billion in the half year ended December 2024. This underpins a strong demand for plasma derived therapies such as Privigen and Hizentra. The company’s ongoing technological advancements including the rollout of the Rika Plasma Donation System and the progress of novel therapies like HEMGENIX® and ANDEMBRY® (Garadacimab) reinforce its leadership in rare disease treatments. CSL’s forward-looking strategy emphasizes sustainable growth through operational efficiencies and global product launches and expecting continued financial momentum into late 2025.
Mesoblast Limited (ASX: MSB)
Mesoblast has achieved a crucial milestone with its FDA approved mesenchymal stromal cell therapy Ryoncil® which was launched commercially in March 2025 for pediatric steroid refractory acute graft versus host disease (SR-aGvHD). Gross revenue from sales of Ryoncil® reached US$13.2M in the first quarter following its launch alongside a strong cash position of around US$162M positioning Mesoblast for ongoing investment in growth and clinical expansion. The company is actively onboarding major U.S. transplant centers and extending insurance coverage ensuring broad patient access. Mesoblast continues to advance clinical trials in inflammatory heart failure and chronic low back pain reinforcing its innovative edge in regenerative medicine while enjoying extended market exclusivity protecting its commercial footprint.
Clarity Pharmaceuticals (ASX: CU6)
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company which strengthened its balance sheet with a $203M institutional placement in mid-2025 increasing its cash reserves to approximately $288M. This capital boost supports the acceleration of pivotal clinical trials for its lead diagnostic and therapeutic agents targeting prostate cancer and neuroendocrine tumors. Clarity’s proprietary Targeted Copper Theranostics (TCTs) platform offers improved imaging and therapeutic potential which is demonstrated by the recent completion of enrolment in its Co-PSMA Phase II trial and ongoing progress towards Phase III registrational studies. Strategic manufacturing partnerships in the United States, notably with SpectronRx further prepare the company for a scalable and timely commercial launch pending regulatory approvals underscoring Clarity’s mission to enhance cancer treatment outcomes.
Orthocell Limited (ASX: OCC)
Orthocell has reached a significant commercial milestone with its first US sales revenue from Remplir™, a collagen nerve repair product that recently received FDA clearance. Early surgical cases in Ohio and Florida initiated in mid-2025 demonstrate Orthocell’s successful entry into the sizable US$1.6B nerve repair market. The company’s focus remains on expanding surgical adoption through specialist distributors while maintaining a strong balance sheet with approximately AUD 28.6M cash on hand as of June 2025. Orthocell’s collagen based medical devices and autologous cell therapies continue to gain traction globally and is supported by regulatory approvals in key markets including Canada, Hong Kong, Brazil and Thailand. With consistent revenue growth in existing markets and strategic US expansion underway, Orthocell is well-positioned for future growth.
ResMed cis solidifying its position as a global leader in sleep and respiratory care technologies. Company reported a net revenue of $1.29B for Q3 2025 which reflected an 8% increase year over year. Its portfolio encompasses advanced devices for sleep apnea and respiratory diseases coupled with innovative software platforms designed to enhance patient monitoring and home care management. Strong earnings, net income of $365M for the quarter and an expansive global footprint underscore the company’s operational excellence. ResMed’s commitment to continuous innovation and acquisitions supports its vision to lead the home health market delivering both improved patient outcomes and sustainable shareholder value in 2025 and beyond.
FAQ About ASX Pharma Companies
What is the best pharma stock to buy in 2025?
Neuren Pharmaceuticals’ (ASX: NEU) patent application for issuance as a patent has been allowed by United States Patent and Trademark Office. Since there are currently no approved treatments for PTHS, it offers a huge opportunity for it.
What is the Biopharma outlook for 2025?
The Biopharma industry is expected to see further growth in 2025, driven by increased R&D budgets leading to innovation amid advancements in AI for drug discovery.
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
